BACKGROUND: The Sonic hedgehog (Shh) signaling pathway is critical for cell growth and differentiation. Impairment of this pathway can result in both birth defects and cancer. Despite its importance in cancer development, the Shh pathway has not been thoroughly investigated in tumorigenesis of brain tumors. In this study, we sought to understand the regulatory roles of GLI1, the immediate downstream activator of the Shh signaling pathway on its downstream target genes PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6 in medulloblastoma and astrocytic tumors. METHODS: We silenced GLI1 expression in medulloblastoma and astrocytic cell lines by transfection of siRNA against GLI1. Subsequently, we performed RT-PCR and quantitative real time RT-PCR (qRT-PCR) to assay the expression of downstream target genes PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6. We also attempted to correlate the pattern of expression of GLI1 and its regulated genes in 14 cell lines and 41 primary medulloblastoma and astrocytoma tumor samples. We also assessed the methylation status of the Cyclin D2 and PTCH1 promoters in these 14 cell lines and 58 primary tumor samples. RESULTS: Silencing expression of GLI1 resulted up-regulation of all target genes in the medulloblastoma cell line, while only PTCH1 was up-regulated in astrocytoma. We also observed methylation of the cyclin D2 promoter in a significant number of astrocytoma cell lines (63%) and primary astrocytoma tumor samples (32%), but not at all in any medulloblastoma samples. PTCH1 promoter methylation was less frequently observed than Cyclin D2 promoter methylation in astrocytomas, and not at all in medulloblastomas. CONCLUSIONS: Our results demonstrate different regulatory mechanisms of Shh-GLI1 signaling. These differences vary according to the downstream target gene affected, the origin of the tissue, as well as epigenetic regulation of some of these genes.
BACKGROUND: The Sonic hedgehog (Shh) signaling pathway is critical for cell growth and differentiation. Impairment of this pathway can result in both birth defects and cancer. Despite its importance in cancer development, the Shh pathway has not been thoroughly investigated in tumorigenesis of brain tumors. In this study, we sought to understand the regulatory roles of GLI1, the immediate downstream activator of the Shh signaling pathway on its downstream target genes PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6 in medulloblastoma and astrocytic tumors. METHODS: We silenced GLI1 expression in medulloblastoma and astrocytic cell lines by transfection of siRNA against GLI1. Subsequently, we performed RT-PCR and quantitative real time RT-PCR (qRT-PCR) to assay the expression of downstream target genes PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6. We also attempted to correlate the pattern of expression of GLI1 and its regulated genes in 14 cell lines and 41 primary medulloblastoma and astrocytomatumor samples. We also assessed the methylation status of the Cyclin D2 and PTCH1 promoters in these 14 cell lines and 58 primary tumor samples. RESULTS: Silencing expression of GLI1 resulted up-regulation of all target genes in the medulloblastoma cell line, while only PTCH1 was up-regulated in astrocytoma. We also observed methylation of the cyclin D2 promoter in a significant number of astrocytoma cell lines (63%) and primary astrocytoma tumor samples (32%), but not at all in any medulloblastoma samples. PTCH1 promoter methylation was less frequently observed than Cyclin D2 promoter methylation in astrocytomas, and not at all in medulloblastomas. CONCLUSIONS: Our results demonstrate different regulatory mechanisms of Shh-GLI1 signaling. These differences vary according to the downstream target gene affected, the origin of the tissue, as well as epigenetic regulation of some of these genes.
Authors: Dong Yin; John M Ong; Jinwei Hu; Julian C Desmond; Norihiko Kawamata; Bindu M Konda; Keith L Black; H Phillip Koeffler Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: C Colin; I Virard; N Baeza; A Tchoghandjian; C Fernandez; C Bouvier; A Calisti; S Tong; P Durbec; D Figarella-Branger Journal: Neuropathol Appl Neurobiol Date: 2007-04-17 Impact factor: 8.090
Authors: Steven A Vokes; Hongkai Ji; Scott McCuine; Toyoaki Tenzen; Shane Giles; Sheng Zhong; William J R Longabaugh; Eric H Davidson; Wing H Wong; Andrew P McMahon Journal: Development Date: 2007-04-18 Impact factor: 6.868
Authors: Matthew McMillin; Cheryl Galindo; Hae Yong Pae; Gabriel Frampton; Pier Luigi Di Patre; Matthew Quinn; Eric Whittington; Sharon DeMorrow Journal: J Hepatol Date: 2014-07-18 Impact factor: 25.083
Authors: Mohd Tayyab; Shirin Farheen; Mubeena Mariyath P M; Nabeela Khanam; M Mobarak Hossain; Mehdi Hayat Shahi Journal: Neuromolecular Med Date: 2019-04-29 Impact factor: 3.843
Authors: Ioannis P Gialmanidis; Vasiliki Bravou; Ilias Petrou; Helen Kourea; Alexandros Mathioudakis; Ioannis Lilis; Helen Papadaki Journal: Lung Date: 2013-07-18 Impact factor: 2.584